Trending at Lumira Ventures

Iterion Therapeutics Confirms Safety of Tegavivint Following Completion of Enrollment in Phase 1/2a Expansion Study in Patients with Desmoid Tumors

Altamash Hashmi Portfolio News, Iterion Therapeutics

– Data provides springboard to advance three additional clinical programs evaluating Tegavivint in acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC) and pediatric cancers. HOUSTON, April 13, 2021 /PRNewswire/ — Iterion Therapeutics, Inc., a venture-backed, clinical stage biotechnology company developing novel …